Is Tirzepatide Covered by Medicaid? State-by-State

Tirzepatide coverage under Medicaid is fragmented, and for the vast majority of enrollees, the drug is severely restricted or unavailable. Whether a state plan will pay for tirzepatide depends on the specific indication it is prescribed for, whether you are enrolled in a fee-for-service or managed care plan, and a tangle of prior authorization rules that differ not just from state to state but from plan to plan within the same state. As of mid-2025, only a minority of states have opted to cover tirzepatide for any indication through their Medicaid programs, and even in those states, actually filling the prescription can require clearing multiple administrative hurdles.

Why Medicaid Coverage Is a Patchwork

Medicaid is jointly funded by the federal government and individual states, but each state has broad discretion over which drugs make it onto its preferred drug list, or formulary. Unlike Medicare, which follows a uniform national benefit structure, Medicaid programs can choose to exclude entire categories of medications. Weight-loss drugs have historically been one of those excluded categories. A 2017 study found that only seven state Medicaid programs offered any drug coverage for obesity treatment at all, and most private marketplace plans were similarly restrictive.¹ The landscape has shifted somewhat since then, but the underlying dynamic of state-by-state decision-making remains.

Adding to the complexity, most Medicaid enrollees are not in traditional fee-for-service (FFS) plans run directly by the state. Instead, they are covered through managed care organizations (MCOs), which are private insurers that contract with the state to administer benefits. Each MCO maintains its own formulary and sets its own prior authorization criteria. That means two people living in the same city, both on Medicaid, can have completely different access to tirzepatide depending on which MCO they were assigned to.

Tirzepatide for Type 2 Diabetes

Tirzepatide was first approved by the FDA as Mounjaro for type 2 diabetes in May 2022. You might assume that a diabetes drug with strong clinical trial results would land on most Medicaid formularies relatively quickly, but that has not happened. A study published in the Annals of Internal Medicine examining Medicaid formularies for cardioprotective diabetes medications found that tirzepatide was “almost entirely restricted” across state plans.² The broader class of GLP-1 receptor agonists (which includes older drugs like liraglutide and semaglutide) fared somewhat better, but access was still far from universal.

Among FFS Medicaid plans, about 60% had some availability of GLP-1 receptor agonists for diabetes. Among managed care plans, the figure was lower, at roughly 48%. The state-level variation within managed care was striking: the share of MCO enrollees with access to GLP-1 receptor agonists ranged from 0% in some states to 99% in others.² The practical result is that even for a clearly indicated diabetes diagnosis, your odds of getting tirzepatide through Medicaid depend heavily on where you live and which plan you are in.

States that restrict tirzepatide for diabetes typically steer prescribers toward older, less expensive diabetes medications first. If you are prescribed tirzepatide for type 2 diabetes and your Medicaid plan does not list it, the usual pathway is a prior authorization request from your prescriber, which often requires documentation that you tried and failed on one or more alternative drugs. Some states deny these requests as a matter of policy; others approve them case by case.

Tirzepatide for Obesity and Weight Management

The coverage picture gets even thinner when tirzepatide is prescribed for weight loss. In November 2023, the FDA approved tirzepatide under the brand name Zepbound specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. But Medicaid programs in most states have traditionally excluded anti-obesity medications from coverage altogether, treating weight loss as outside the scope of medical necessity.

That exclusion has begun to erode. Research tracking state Medicaid policies found that by mid-2025, 17 states had at some point covered obesity-indicated GLP-1 medications, including tirzepatide and semaglutide.³ That leaves roughly two-thirds of states without coverage for these drugs when prescribed purely for weight management. If you are on Medicaid in one of those remaining states and your doctor writes a Zepbound prescription for obesity, the claim will almost certainly be denied.

In the states that have added coverage, uptake has been measurable. Coverage increased prescriptions for obesity-indicated GLP-1 medications by about 0.82 per 100 enrollee-months after nine quarters, according to the same research. Interestingly, the study also found that adding obesity coverage did not cause a spillover effect on GLP-1 prescribing for diabetes, which suggests that off-label use of diabetes formulations as a workaround for weight loss has not been a common pattern in Medicaid.³

The Sleep Apnea Route

A newer wrinkle in tirzepatide’s coverage story involves obstructive sleep apnea. In late 2024, the FDA approved Zepbound for this condition, making tirzepatide the first drug approved specifically to treat sleep apnea in people with obesity. As of January 2025, Medicare began covering tirzepatide for this indication, a significant development given that Medicare has historically excluded weight-loss drugs entirely.⁴

For Medicaid enrollees, the sleep apnea indication could create a new pathway to coverage even in states that exclude anti-obesity drugs. If a patient has a documented diagnosis of obstructive sleep apnea and obesity, a prescriber can argue that the drug is being prescribed for a condition the state does cover, rather than for weight loss per se. Whether individual states and MCOs honor this distinction is still unfolding. Some states may add tirzepatide to their formularies specifically for sleep apnea while continuing to exclude it for obesity; others may be slower to act. Dual-eligible individuals, those enrolled in both Medicare and Medicaid, may have a smoother path because Medicare’s coverage decision can take precedence for the drug benefit.

Why States Hesitate: The Budget Impact

The main reason states restrict tirzepatide is cost. At list price, GLP-1 receptor agonists for obesity are expensive, and Medicaid covers a large population with high rates of obesity. One analysis estimated that the average per-member, per-month cost contributed by weight-loss GLP-1 medications was $2.65, and that covering the entire U.S. Medicaid population of roughly 82 million people would run about $2.7 billion annually, approximately $1.7 billion more than what was actually being spent as of early 2024.⁵

Manufacturer rebates soften the blow but do not eliminate it. The NBER analysis of states that covered obesity-indicated GLP-1s found that rebates reduced net spending by about 24% compared to gross reimbursements. Even after rebates, coverage across the 17 states that had adopted it increased net Medicaid spending by around $2.68 billion per year. Extending coverage to the remaining states would generate an estimated further $3.63 billion in annual net spending.³ For state legislators balancing tight budgets, those are big numbers, and the political pressure to avoid a pharmacy spending spike can outweigh the clinical evidence for coverage.

Many states use prior authorization requirements as a pressure valve. Rather than flatly refusing to cover GLP-1 receptor agonists, they build in administrative barriers that limit the number of enrollees who actually fill prescriptions. Step therapy, or “fail first,” policies require patients to try cheaper medications before the state will authorize a GLP-1. Some states require documentation of a minimum body mass index, a certain number of failed diet and exercise attempts, or specialist referrals. These requirements add months to the process and cause a significant number of patients to drop out before ever receiving the drug.

Do Long-Term Savings Justify the Drug Cost?

Proponents of broader coverage argue that the upfront cost of tirzepatide is at least partially offset by reductions in downstream healthcare spending. Obesity drives costs across nearly every medical category, from cardiovascular disease and joint replacements to diabetes management and hospital admissions. If a drug meaningfully reduces weight and keeps it off, the theory goes, it should save money over time.

There is some early evidence supporting that idea. A study of older adults with obesity found that, excluding the cost of the drug itself, tirzepatide users had all-cause healthcare costs that were about $145 per person per month lower than controls during the six-to-twelve-month window after starting treatment, a reduction of roughly 12%. By twelve to eighteen months, the gap widened to about $319 per person per month, a 25% reduction.⁶ Those are meaningful savings, driven largely by fewer hospitalizations and medical procedures.

But when you add the price of the drug back into the equation, the math gets harder to defend at current prices. A cost-effectiveness analysis published in JAMA Health Forum modeled the lifetime health effects of tirzepatide plus lifestyle modification versus lifestyle modification alone. Tirzepatide did produce the lowest background healthcare costs and the least productivity loss, thanks to improved health outcomes. However, the high treatment cost pushed the incremental cost-effectiveness ratio to about $197,000 per quality-adjusted life year gained.⁷ That figure is well above the $100,000-to-$150,000 threshold that many health economists use as a rough benchmark for good value. Semaglutide fared even worse in the same analysis, at roughly $468,000 per quality-adjusted life year. The takeaway is that tirzepatide’s health benefits are real, but the drug needs to come down in price, or stay effective for longer than current data can confirm, before the economics clearly favor universal Medicaid coverage.

Managed Care Adds Another Layer of Unpredictability

Even when a state officially adds a GLP-1 receptor agonist to its Medicaid formulary, the experience on the ground can differ dramatically between managed care organizations operating within that state. The Annals of Internal Medicine study highlighted this gap clearly: the proportion of MCO enrollees with access to GLP-1 receptor agonists varied from 0% to 99% depending on the state, and the variation for other diabetes drug classes was similarly wide.²

This means that checking your state’s official Medicaid formulary is not sufficient. You need to check the formulary of your specific MCO plan, which is sometimes available online and sometimes requires a phone call. If your MCO does not cover tirzepatide, switching to a different MCO within your state may be possible during open enrollment periods, though this involves changing your entire network of providers. Some states allow mid-year plan changes under certain circumstances, but the rules vary.

Fee-for-service Medicaid, where available, at least offers a single formulary to check. But FFS enrollment has been declining for years as states shift more of their Medicaid populations into managed care. In practice, the MCO formulary is the one that matters for most enrollees.

Practical Steps if You Are on Medicaid

If you are trying to get tirzepatide covered, a few strategies can improve your odds, though none guarantee success in a state that excludes the drug.

Check your plan’s formulary first: Look up your specific MCO’s preferred drug list, not just your state’s general Medicaid formulary. Many MCOs publish searchable formularies on their websites. If tirzepatide is listed, note whether it is on a preferred or non-preferred tier, as this affects your copay and the likelihood of prior authorization requirements.
Ask your prescriber about prior authorization: Even when tirzepatide is not on the formulary, most states have a process for requesting exceptions. Your doctor will need to submit clinical documentation, which typically includes your BMI, relevant comorbidities like diabetes or sleep apnea, and a record of other treatments you have tried. The stronger the medical justification, the better the chance of approval.
Consider the indication: If you have both obesity and type 2 diabetes, or obesity and obstructive sleep apnea, your prescriber may have more success requesting coverage under the diabetes or sleep apnea indication than under the weight-management indication. This is not gaming the system; if you genuinely have the condition, it is a legitimate clinical rationale.
Appeal denials: Medicaid plans are required to offer an appeals process. If your prior authorization is denied, you can request an internal appeal and, if that fails, an external or fair hearing review. Denials are overturned often enough that the process is worth pursuing, especially with supporting documentation from your prescriber.
Look into manufacturer programs: Eli Lilly, which manufactures tirzepatide, has offered savings programs and patient assistance for people who meet certain income criteria. These programs change frequently, so check the manufacturer’s current offerings. They are not a substitute for insurance coverage, but they can bridge a gap while you navigate the prior authorization process.

Federal Legislative Efforts

The most commonly discussed federal proposal is the Treat and Reduce Obesity Act, known as TROA, which has been introduced in various forms in Congress over several sessions. TROA would, among other things, remove the statutory exclusion that prevents Medicare Part D from covering anti-obesity medications.⁸ While TROA is focused on Medicare rather than Medicaid, a change in Medicare policy tends to have downstream effects. When Medicare covers a drug, it signals legitimacy to state Medicaid programs and private insurers, and it can shift the political calculus for state legislators who were hesitant to cover the same drug class.

The FDA’s approval of tirzepatide for sleep apnea has already demonstrated this dynamic. Because sleep apnea is not classified as obesity, Medicare’s statutory exclusion of weight-loss drugs did not apply, and coverage followed quickly. Some health policy researchers have proposed using the waiver authority of the Center for Medicare and Medicaid Innovation to pilot broader obesity drug coverage and study its budget impact before committing to a permanent policy change. If pilot data showed that coverage reduced hospitalizations and other spending enough to partially pay for itself, that would give both Medicare and state Medicaid programs stronger fiscal justification to expand access.

The Equity Dimension

The people most affected by Medicaid’s coverage gaps for tirzepatide are disproportionately from communities that already face higher rates of obesity and its complications. Medicaid enrollees are more likely to be low-income, and obesity prevalence is strongly correlated with socioeconomic status. When private insurers and Medicare gradually expand access to newer obesity medications while Medicaid lags behind, the result is a treatment gap that tracks closely with income and, by extension, with race and ethnicity.

This is not a new pattern. The 2017 study that found only seven state Medicaid programs covering any obesity drugs also documented thin coverage in marketplace plans, where only about 11% offered some coverage and only in nine states.¹ Coverage has improved in the private market since then, partly driven by employer demand and partly by the high-profile clinical trial results for GLP-1 drugs. But Medicaid has been slower to follow, and the gap between what a commercially insured patient can access and what a Medicaid enrollee can access has widened as newer, more effective drugs have come to market.

The cost-effectiveness data adds a difficult wrinkle to this discussion. If tirzepatide’s cost-effectiveness ratio sits above conventional thresholds at current prices, some policymakers argue that covering it would divert limited Medicaid dollars from other services that deliver more health per dollar. Others counter that cost-effectiveness thresholds were developed in a context that did not account for the scale of the obesity epidemic or the long-term fiscal burden of untreated obesity on public programs. Where you land on that argument depends partly on how much weight you give to short-term budget constraints versus long-term health outcomes, a tension that state Medicaid directors navigate with every formulary decision.

How Quickly the Landscape Is Changing

Compared to even two years ago, the pace of change in this space is fast. The number of states covering obesity-indicated GLP-1 medications has grown from seven in 2017 to 17 by mid-2025. The FDA has added new indications for tirzepatide beyond diabetes and obesity, and each new indication creates a potential new coverage pathway. Manufacturer rebate negotiations continue to bring down net costs for state programs, and the entry of additional competitors into the GLP-1 market could put further downward pressure on pricing.

At the same time, state budgets remain tight, and the political environment around government spending on healthcare is uncertain. Some states that added coverage may scale it back if costs exceed projections. Others may add coverage for the first time as the clinical evidence accumulates and as peer states demonstrate that the sky did not fall after opening their formularies. If you are on Medicaid and interested in tirzepatide, it is worth rechecking your plan’s formulary periodically, because the policy your state had six months ago may not be the policy it has today.

1
Nature / International Journal of Obesity. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity
2
Annals of Internal Medicine. Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program
3
NBER. Medicaid Coverage for Obesity Medications: Utilization and Net-of-Rebate Spending
4
JAMA Health Forum. Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity
5
American Journal of Preventive Medicine. Medicaid State Level Cost Impact of Glucagon-like Peptide-1 Coverage for Obesity
6
Diabetes, Obesity and Metabolism. Tirzepatide Cuts Health Care Costs in Older Adults With Obesity
7
PubMed Central. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
8
Springer Link / PubMed Central. Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform